InsidersTradesSigma
Total declarations
Companies
▲ Purchases (23 ops.)
▼ Sales (10 ops.)
Insider track record
Board DirectorDisclosed buys
23
Disclosed sells
10
T+90 hit rate
50%
T+90 mean return
+2.8%
Across 20 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the full record of transactions filed by English Aron R., Director. Director active across 5 companies, notably Anebulo Pharmaceuticals, Inc.. Aggregated, 45 filings have been published. Split: 23 buys · 10 sells. Total volume traded: €15.2m. Activity tracked since 6 May 2021. The latest transaction was filed on 28 November 2025 (Cession). Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations45 total
1,307 shares@ US$27.08552.9% of flowCommon StockSEC:0000921895-25-003249:0
101 shares@ US$26.81680.2% of flowCommon StockSEC:0000921895-25-003249:1
3,412 shares@ US$27.02887.5% of flowCommon StockSEC:0000921895-25-003202:0
27,003 shares@ US$26.835759.1% of flowCommon StockSEC:0000921895-25-003202:1
1,725 shares@ US$26.93753.8% of flowCommon StockSEC:0000921895-25-003202:2
2,247 shares@ US$27.004.9% of flowCommon StockSEC:0000921895-25-003153:0
400 shares@ US$27.000.9% of flowCommon StockSEC:0000921895-25-003153:1
12,334 shares@ US$7.001229.4% of flowCommon StockSEC:0000950170-25-073196:0
5,098 shares@ US$7.001412.1% of flowCommon StockSEC:0000950170-25-069576:0
24,543 shares@ US$7.082758.5% of flowCommon StockSEC:0000950170-25-066222:0
104,738 shares@ US$5.3533.7% of flowCommon StockSEC:0000921895-25-000835:0
Ideal exit: 13 Dec 2025 (T+270)
9,793 shares@ US$5.07413.0% of flowCommon StockSEC:0000921895-25-000797:0
Ideal exit: 8 Dec 2025 (T+270)
13,849 shares@ US$4.64573.9% of flowCommon StockSEC:0000921895-25-000751:0
Ideal exit: 5 Dec 2025 (T+270)
10,101,010 shares@ US$0.9930.6% of flowCommon StockSEC:0001493152-24-052101:0
Ideal exit: 19 Sept 2025 (T+270)
1,246 shares@ US$5.24890.4% of flowCommon StockSEC:0000921895-24-003006:0
Ideal exit: 14 Sept 2025 (T+270)
2,787 shares@ US$4.95690.9% of flowCommon StockSEC:0000921895-24-002931:0
Ideal exit: 5 Sept 2025 (T+270)
102,484 shares@ US$5.853835.4% of flowCommon StockSEC:0000921895-24-002147:0
Ideal exit: 14 Jun 2025 (T+270)
7,652 shares@ US$5.38812.5% of flowCommon StockSEC:0000921895-24-002119:0
Ideal exit: 6 Jun 2025 (T+270)
5,749 shares@ US$5.21121.8% of flowCommon StockSEC:0000921895-24-001608:0
Ideal exit: 13 Apr 2025 (T+270)
13,275 shares@ US$5.07494.1% of flowCommon StockSEC:0000921895-24-001574:0
Ideal exit: 8 Apr 2025 (T+270)
9,703 shares@ US$5.19023.0% of flowCommon StockSEC:0000921895-24-001574:1
Ideal exit: 12 Apr 2025 (T+270)
39,248 shares@ US$4.749411.3% of flowCommon StockSEC:0000921895-24-001551:0
Ideal exit: 4 Apr 2025 (T+270)
1,597,833 shares@ US$0.353.1% of flowCommon SharesSEC:0000921895-24-000718:0
1,575,057 shares@ US$0.353.0% of flowCommon SharesSEC:0001193805-24-000084:0
28,191,998 shares@ US$0.3553.9% of flowCommon SharesSEC:0001193805-24-000084:1
25 of 45 declarations
About English Aron R.
English Aron R. serves as a Director at Anebulo Pharmaceuticals, Inc. As a director, he participates in the governance of the company and strategic decision-making. His experience in the pharmaceutical sector allows him to provide valuable insights to board discussions. English Aron R. is committed to supporting innovation and sustainable growth within Anebulo Pharmaceuticals.
